Hospital-Acquired Pneumonia Drugs Market by Clinical Phase 1, 2 and 3 Drugs – Amikacin Inhale, Ceftazidime (Avibactum), Ceftolozane (Tazobactam), Plazomicin, Synflorix Vaccine, and Tedizolid Phosphate and Forecast 2017-2021

Hospital-Acquired Pneumonia Drugs Market by Clinical Phase 1, 2 and 3 Drugs – Amikacin Inhale, Ceftazidime (Avibactum), Ceftolozane (Tazobactam), Plazomicin, Synflorix Vaccine, and Tedizolid Phosphate and Forecast 2017-2021

Hospital-acquired pneumonia (HAP) or nosocomial pneumonia is caused due to the most common pathogens such as gram-negative bacilli and Staphylococcus aureus; whereas, antibiotic-resistant organisms are an important concern. There are two subtypes of HAP: Ventilator-associated pneumonia (VAP) and Healthcare-associated pneumonia (HCAP). Hospital-acquired pneumonia also called as healthcare associated pneumonia, nosocomial or ventilator associated pneumonia is caused due to infections acquired in hospital premise. The disease is different from community acquired pneumonia in that the former is mainly caused due to multi drug resistant microorganisms. Majority of these infections are caused by microorganism’s resistance to conventional drugs. These include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Besides prompt antibiotic treatment, supportive measure for organ failure (such as cardiac decompensation) are also important.

The global hospital-acquired pneumonia (HAP) drugs market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the clinical pipeline analysis of phase 1, 2 and 3 drugs such as Amikacin Inhale, Ceftazidime (Avibactum), Ceftolozane (Tazobactam), Plazomicin, Synflorix Vaccine, and Tedizolid Phosphate, and forecasts growth trends (CAGR% – 2017 to 2021).

The global hospital-acquired pneumonia drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global hospital-acquired pneumonia drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global hospital-acquired pneumonia drugs market and included in this report are Achaogen, Inc., Aridis Pharmaceuticals, AstraZeneca plc, Cubist Pharmaceuticals, Inc., GlaxoSmithKline, Inc., Meiji Seika Pharma Co. Ltd., Merck & Co. Inc., Sanofi SA, and Valneva SE.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Hospital Acquired Pneumonia Drugs Market

1. Pipeline Analysis (Phase 3 Drugs)
1.1. Amikacin Inhale
1.2. Ceftazidime (Avibactum)
1.3. Ceftolozane (Tazobactam)
1.4. Plazomicin
1.5. Synflorix Vaccine
1.6. Tedizolid phosphate

2. Pipeline Analysis (Phase 1 and 2 Drugs)
2.1. AR-101 (or KBPA101) and AR-104 (or KBPA104)
2.2. AR-201 (or KBRV201)
2.3. AR-301 or KBSA301
2.4. AR-401 (or KBAB401)
2.5. BAL30072
2.6. GSK 2189242A
2.7. IC43
2.8. ME1100
2.9. MEDI4893
2.10. V114

3. Company Profiles
3.1. Achaogen, Inc.
3.2. Aridis Pharmaceuticals
3.3. AstraZeneca plc
3.4. Cubist Pharmaceuticals, Inc.
3.5. GlaxoSmithKline, Inc.
3.6. Meiji Seika Pharma Co. Ltd.
3.7. Merck & Co. Inc.
3.8. Sanofi SA
3.9. Valneva SE

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*